Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?